Company Projected Revenue: Altimmune Inc (ALT)

A partnership with a pharma behemoth for final testing of its obesity drug will become the key driver for Altimmune, Inc. (ALT). This chart of the company's projected sales dynamics is available in the GURU.Markets terminal, where 0.00 indicates the current level of market expectations. The business model relies on full outsourcing of production and trials, yet the high scalability of patents allows the company to monetize developments through lucrative licensing.

ALT - Altimmune, Inc. Company Future Sales over the range 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Altimmune Inc (ALT)

- stock value and consensus price forecast:

Price Chart Altimmune, Inc.|ALT - Average Forecast Price

- company stock exchange capitalization indicators:

Market Value Altimmune Inc|ALT - Total Company Value

- balance sheet equity data:

Book Value per Share Altimmune|ALT - Book Valuation of Business|Market Value to Book Value Ratio altimmune.com|ALT - Company Total Asset Base

- debt obligations and liquidity statistics:

- earnings and market ratios statistics:

ALT - Net Financial Result|Expected Profit Altimmune, Inc.|ALT - Price to Earnings Ratio|Future Price to Earnings Altimmune|ALT - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Altimmune Inc|ALT - Operating profit EBITDA|Earnings per share for the last twelve months Altimmune|ALT - Earnings per share for the last 12 months|Quarterly EPS earnings growth altimmune.com|ALT - Earnings per share growth rate in current year|Expected earnings per share growth for next year Altimmune, Inc.

- revenue and sales proceeds data:

ALT - Company Sales Revenue|Projected Sales Volume Altimmune, Inc.|ALT - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Altimmune Inc

Comprehensive company analysis:ALT Altimmune, Inc.

For Altimmune, Inc. (ALT), which competes with behemoths in the obesity peptide drug segment, this indicator serves as a gauge of market expectations for future revenue. By analyzing the future sales volume chart, an investor assesses the aggregate value of upcoming revenues, which for Altimmune, Inc. (ALT) correlates directly with the success of clinical trials regarding the preservation of muscle mass.

Competing companies